Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.64 |
| ▸ | AKT2 | P31751 | 13/20 | 0.64 |
| ▸ | AKT3 | Q9Y243 | 13/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31455419 | 0.96 | AKT1 (0.63) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31420269 | 0.95 | AKT1 (0.66) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31420356 | 0.93 | AKT1 (0.68) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31455377 | 0.90 | AKT1 (0.51) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL31420259 | 0.86 | AKT1 (0.60) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31455269 | 0.85 | AKT1 (0.58) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL31455118 | 0.84 | AKT1 (0.64) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL25385750 | 0.82 | AKT1 (0.80) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30574827 | 0.82 | AKT1 (0.80) | AKT1AKT2AKT3CYP3A4CYP2D6 | |
| SCHEMBL30802471 | 0.81 | AKT1 (0.68) | AKT1AKT2AKT3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059577-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS FOR USE AS AKT1 INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |